• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24038 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Testing of a method for assessing the internal validity of guideline recommendations, using the example of evidence-based guidelines on preoperative diagnostics]
2015     National Institute for Health and Care Excellence (NICE) Vortioxetine for treating major depressive episodes. NICE technology appraisal guidance 367
2015     NIHR Health Technology Assessment programme The relative clinical and cost-effectiveness of three contrasting approaches to partner notification for curable sexually transmitted infections (STIs): a cluster randomised trial in primary care
2015     NIHR Health Services and Delivery Research programme Intentional rounding in hospital wards: What works, for whom and in what circumstances?
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2015     National Institute for Health and Care Excellence (NICE) Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. NICE technology appraisal guidance 369
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015     National Institute for Health and Care Excellence (NICE) Bortezomib for previously untreated mantle cell lymphoma. NICE technology appraisal guidance 370
2015     NIHR Health Technology Assessment programme Clinical diagnostic accuracy of rapid detection of healthcare-associated bloodstream infection in critical care using multi-pathogen real-time polymerase chain reaction (RT-PCR) technology
2015     NIHR Horizon Scanning Centre (NIHR HSC) Lonsurf (trifluridine and tipiracil hydrochloride) for metastatic colorectal cancer – third line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (Addendum to Commission A15-07)]
2015     National Institute for Health and Care Excellence (NICE) Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 373
2015     NIHR Horizon Scanning Centre (NIHR HSC) AZD9291 for locally advanced or metastatic, EGFR and T790M mutation positive non-small cell lung cancer – second line
2015     Institute of Health Economics (IHE) A systematic review of the measurement properties of self-report instruments that assess presenteeism
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study
2015     NIHR Health Services and Delivery Research programme The SHAPE project: Supporting adults with High-functioning Autism and asPerger syndromE. Mapping and evaluating specialist autism team service models
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sodium thiosulfate for prevention of hearing loss in children receiving cisplatin chemotherapy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for small cell lung cancer – first line, in combination with etoposide and platinum therapy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (addendum to commission A15-10)]
2015     The Swedish Council on Health Technology Assessment (SBU) [Arginine and caries prevention]
2015     NIHR Horizon Scanning Centre (NIHR HSC) Selumetinib for metastatic uveal melanoma – first line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Services and Delivery Research programme Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ibrutinib (Imbruvica) for Waldenström's macroglobulinaemia
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley's, McMurray's and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis
2015     NIHR Health Services and Delivery Research programme The value and cost of different forms of information on oral health status and risk given to patients following a check-up in dental practice
2015     NIHR Horizon Scanning Centre (NIHR HSC) Nimotuzumab for advanced pancreatic cancer – second line
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Public health interventions to reduce the secondary spread of measles
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation
2015     NIHR Health Technology Assessment programme The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation
2015     NIHR Health Technology Assessment programme The PAndemic INfluenza Triage in the Emergency Department (PAINTED) pilot cohort study
2015     Belgian Health Care Knowledge Centre (KCE) Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers
2015     NIHR Horizon Scanning Centre (NIHR HSC) Evofosfamide for locally advanced, unresectable or metastatic pancreatic cancer – first line in combination with gemcitabine
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening
2015     HAYES, Inc. Absorbable perirectal spacer (SpaceOAR System; Augmenix Inc.) during radiation therapy for prostate cancer
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ixekizumab for moderate to severe chronic plaque psoriasis
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of acamprosate calcium for alcoholism: a review of the clinical effectiveness, safety, and guidelines
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis
2015     Belgian Health Care Knowledge Centre (KCE) Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology
2015     HAYES, Inc. Adalimumab (humira) for treatment of pediatric Crohn's disease
2015     NIHR Horizon Scanning Centre (NIHR HSC) Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis
2015     Belgian Health Care Knowledge Centre (KCE) Cardiovascular pre-participation screening in young athletes
2015     HAYES, Inc. Augment bone graft (Wright Medical Group Inc.) for bone regeneration in ankle and/or hindfoot fusions
2015     NIHR Horizon Scanning Centre (NIHR HSC) Masitinib for amyotrophic lateral sclerosis – add-on therapy to riluzole
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Rapid detection of health-care-associated bloodstream infection in critical care using multipathogen real-time polymerase chain reaction technology: a diagnostic accuracy study and systematic review
2015     Belgian Health Care Knowledge Centre (KCE) Non-invasive markers of subclinical atherosclerosis for predicting a primary cardiovascular event: a rapid systematic review
2015     HAYES, Inc. Eliglustat (Cerdelga) for Gaucher disease type 1
2015     NIHR Horizon Scanning Centre (NIHR HSC) Reslizumab for eosinophilic asthma
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib (Addendum to Commission A15-13)]
2015     NIHR Health Technology Assessment programme Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial)
2015     NIHR Public Health Research (PHR) programme Preschoolers in the Playground: a pilot cluster randomised controlled trial of a physical activity intervention for children aged 18 months to 4 years
2015     HAYES, Inc. Elosulfase alpha (Vimizim) for treatment of Morquio A Syndrome
2015     NIHR Horizon Scanning Centre (NIHR HSC) Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care
2015     HAYES, Inc. Flibanserin (Addyi) for premenopausal women with hypoactive sexual desire disorder
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sodium zirconium cyclosilicate for hyperkalaemia – first line
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Endovenous interventions on varicose veins of the leg
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension]
2015     Agency for Healthcare Research and Quality (AHRQ) Menopausal symptoms: comparative effectiveness review of therapies
2015     Agency for Healthcare Research and Quality (AHRQ) Public reporting of cost measures in health: an environmental scan of current practices and assessment of consumer centeredness
2015     Scottish Health Technologies Group (SHTG) Magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids
2015     HAYES, Inc. iFuse implant system (SI-BONE Inc.) for sacroiliac joint fusion for treatment of low back pain
2015     NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir in combination with sofosbuvir (with or without ribavirin) for chronic hepatitis C
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Hypoglossal nerve stimulation (HGNS) for treatment of obstructive sleep apnea
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2015     NIHR Health Technology Assessment programme A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT
2015     Agency for Healthcare Research and Quality (AHRQ) Treatments for Fibromyalgia in Adult Subgroups
2015     NIHR Health Services and Delivery Research programme Evaluating the evidence on employee engagement and its potential benefits to NHS staff: a narrative synthesis of the literature
2015     HAYES, Inc. Intravenous golimumab (Simponi Aria) for treatment of active rheumatoid arthritis
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sarilumab for moderate to severe active rheumatoid arthritis
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Prophylactic insertion of a gastrostomy for nutritional support in patients with head and neck cancer
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide (Addendum to Commission A15-15)]
2015     NIHR Health Technology Assessment programme Initiating change locally in bullying and aggression through the school environment (INCLUSIVE): a pilot randomised controlled trial
2015     NIHR Health Technology Assessment programme Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial 'in hibernation', ready for rapid activation
2015     Agency for Healthcare Research and Quality (AHRQ) Pain management injection therapies for low back pain
2015     HAYES, Inc. Laminotomy for lumbar spinal stenosis
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for chronic plaque psoriasis – second line
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Oncological safety and patient-related outcomes of autologous fat grafting in breast reconstruction after breast cancer surgery
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vortioxetine (Addendum to Commission A15-16)]
2015     NIHR Health Technology Assessment programme Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model
2015     Agency for Healthcare Research and Quality (AHRQ) Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review to update the U.S. Preventive Services Task Force Recommendation
2015     HAYES, Inc. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults
2015     NIHR Horizon Scanning Centre (NIHR HSC) Cx601 (Alofisel®) for complex perianal fistula in adults with non-active or mildly-active luminal Crohn's disease – second line
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Drug eluting balloons and stents for symptomatic peripheral arterial disease
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study
2015     NIHR Health Technology Assessment programme Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme
2015     Agency for Healthcare Research and Quality (AHRQ) Management of postpartum hemorrhage
2015     HAYES, Inc. Lumacaftor-ivacaftor (Orkambi) for treatment of cystic fibrosis
2015     NIHR Horizon Scanning Centre (NIHR HSC) Tildrakizumab for moderate to severe plaque psoriasis